Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Semagacestat for Alzheimer's Patients
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT01035138
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT01029795
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain
A Study for Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2605541Drug: insulin glargine
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 289
- Registration Number
- NCT01027871
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malaga, Spain
A Study of Tadalafil After Radical Prostatectomy
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 583
- Registration Number
- NCT01026818
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Withington, Manchester, United Kingdom
A Study for Participants With Small-Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: LY2523355Drug: Granulocyte colony-stimulating factor (G-CSF)
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 64
- Registration Number
- NCT01025284
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania
A Study of LY2599506 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDrug: LY2599506
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 78
- Registration Number
- NCT01024244
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Cruz De Tenerife, Spain
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
- First Posted Date
- 2009-11-26
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 109
- Registration Number
- NCT01020786
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 524
- Registration Number
- NCT01018680
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
A Study for Adults With Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: LY2525623 IntravenousDrug: Placebo IntravenousDrug: Placebo SubcutaneousDrug: LY2525623 Subcutaneous
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT01018810
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
- Conditions
- CancerSolid Tumor
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT01017731
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States